HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Enterocolitis — Clinical Guidelines

Overview

Enterocolitis, often associated with immune checkpoint inhibitors (ICIs), represents a severe inflammatory condition affecting the gastrointestinal tract, leading to significant morbidity and potential mortality if not promptly managed. 7

Diagnosis

Clinical Presentation: Diarrhea, abdominal pain, and signs of systemic inflammation.

Laboratory Tests: Elevated inflammatory markers (e.g., CRP, ESR), electrolyte imbalances.

Imaging: Abdominal CT or MRI may show bowel wall thickening or other inflammatory changes.

Endoscopy: Essential for visualizing mucosal inflammation and obtaining biopsies if necessary. 7

Management

First-Line Treatments:

- Corticosteroids: High-dose glucocorticoids (e.g., prednisone 1-2 mg/kg/day) are typically initiated. 7 - Discontinuation of ICIs: Temporarily halt ICI therapy until symptoms resolve.

Adjunctive Treatments:

- Immunosuppressive Agents: If corticosteroids are insufficient, consider agents like infliximab, mycophenolate mofetil, or cyclosporine. 7 - Supportive Care: Fluid resuscitation, electrolyte correction, and nutritional support.

Special Populations

Elderly: Increased susceptibility to severe complications; careful monitoring and individualized treatment plans are crucial. 2

Comorbidities: Patients with pre-existing conditions like liver dysfunction or multiorgan failure require heightened vigilance and multidisciplinary care. 2 6

Key Recommendations

Prompt Recognition and Early Intervention: Early identification of enterocolitis symptoms and immediate initiation of anti-inflammatory therapy is critical to prevent severe complications. (Evidence: Moderate 7)

Use of High-Dose Corticosteroids: Initiate high-dose corticosteroids as first-line treatment for immune checkpoint inhibitor-induced enterocolitis. (Evidence: Moderate 7)

Multidisciplinary Approach: Engage gastroenterologists and other specialists for comprehensive management, especially in complex cases involving multiple organ systems. (Evidence: Expert opinion 7)

Monitor for Concurrent Adverse Events: Maintain a high index of suspicion for concurrent immune-related adverse events, particularly in patients with multiorgan involvement. (Evidence: Moderate 2 6)

References

1 Wang B, Zhuang S, Lin S, Lin J, Zeng W, Du B et al.. Analysis of risk factors for immune checkpoint inhibitor-associated liver injury: a retrospective analysis based on clinical study and real-world data. Hepatology international 2025. link 2 Verma T, Jawadi A, Ahmed S. Management of multiorgan failure caused by immune checkpoint inhibitor toxicity. BMJ case reports 2025. link 3 Li ZM, Zheng YF, Xu PH, Wang JY, He RL, Li HX et al.. Analysis of pulmonary adverse events associated with immune checkpoint inhibitors based on FAERS and VigiBase database. European journal of pharmacology 2025. link 4 Okamoto K, Takizawa J, Ueda H, Narumi K, Kobayashi M. Effect of Acid Suppressants on Adverse Events of Immune Checkpoint Inhibitors Using Real-world Databases. Anticancer research 2025. link 5 Godfrey H, Jedlowski P, Thiede R. Severe cutaneous adverse reactions associated with the immune checkpoint inhibitors: A case/non-case analysis using the Food and Drug Administration Adverse Event Reporting System. The Australasian journal of dermatology 2024. link 6 Dougan M, Wang Y, Rubio-Tapia A, Lim JK. AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review. Gastroenterology 2021. link 7 Powell N, Ibraheim H, Raine T, Speight RA, Papa S, Brain O et al.. British Society of Gastroenterology endorsed guidance for the management of immune checkpoint inhibitor-induced enterocolitis. The lancet. Gastroenterology & hepatology 2020. link30014-5) 8 Noseda R, Bertoli R, Müller L, Ceschi A. Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports. Journal for immunotherapy of cancer 2019. link 9 Campistol JM, de Fijter JW, Flechner SM, Langone A, Morelon E, Stockfleth E. mTOR inhibitor-associated dermatologic and mucosal problems. Clinical transplantation 2010. link

Enterocolitis